# Evaluating CB2 Receptor Agonist Effects on Neuropathic Pain > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cb2-receptor-agonist-neuropathic-pain/ > **Published:** 2026-04-27T05:02:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:01:24-04:00 > **Clinical Summary:** Explore the role of CB2 receptor agonist neuropathic pain treatment in reducing evoked and spontaneous pain in preclinical models. --- CED Clinical Relevance  #70Notable Clinical Interest Evidence Brief | CED ClinicCB₂ cannabinoid receptor agonist LY2828360 reduces both evoked and spontaneous neuropathic pain in preclinical spared nerve injury model. Neuropathic Pain[Cb2 Receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/)Preclinical Research[Cannabinoid Medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/)Pain Management Table of Contents - [Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CB](#Assessments_of_Evoked_and_Spontaneous_Pain_Following_Administration_of_Gabapentin_and_the_Cannabinoid_CB) - [FAQ](#FAQ)[What is LY2828360 and how does it work for neuropathic pain?](#What_is_LY2828360_and_how_does_it_work_for_neuropathic_pain) - [How does CB₂ receptor targeting differ from traditional cannabinoid approaches?](#How_does_CB_receptor_targeting_differ_from_traditional_cannabinoid_approaches) - [What types of neuropathic pain did this study evaluate?](#What_types_of_neuropathic_pain_did_this_study_evaluate) - [How significant were the pain reduction effects compared to existing treatments?](#How_significant_were_the_pain_reduction_effects_compared_to_existing_treatments) - [What are the clinical implications for human neuropathic pain treatment?](#What_are_the_clinical_implications_for_human_neuropathic_pain_treatment) - [Related](#Related) ## Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CB CB₂ cannabinoid receptor agonist LY2828360 reduces both evoked and spontaneous neuropathic pain in preclinical spared nerve injury model. What This Study Teaches Us This study demonstrates that CB₂ receptor activation can suppress both the sensory and affective components of neuropathic pain in a validated preclinical model. The within-subjects design strengthens the finding that a single intervention can address multiple pain dimensions simultaneously. Why This Matters Neuropathic pain remains notoriously difficult to treat, with many patients experiencing inadequate relief from conventional therapies. Understanding CB₂-mediated analgesia could inform development of cannabinoid medicines targeting both the sensory experience and emotional suffering of chronic pain. Study Snapshot Study Type Preclinical Experimental Study Population Rats with spared nerve injury (SNI) model, specific n not stated Intervention LY2828360 (CB₂ receptor agonist) 10 mg/kg intraperitoneally, chronic dosing Comparator Vehicle control and gabapentin 100 mg/kg as reference analgesic Primary Outcome Conditioned place preference (CPP) for spontaneous pain assessment and paw withdrawal thresholds for evoked pain Key Finding LY2828360 prevented gabapentin-induced CPP development and improved withdrawal thresholds Journal Cannabis and [Cannabinoid Research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) Year Not specified in abstract Clinical Bottom Line CB₂ receptor agonism shows promise for comprehensive neuropathic pain management in preclinical models. This mechanism warrants investigation in human studies, particularly given the peripheral expression of CB₂ receptors and potential for reduced central nervous system side effects. What This Paper Does Not Show This study provides no data on human efficacy, safety, or tolerability of CB₂ agonists. The optimal dosing, duration of effect, and potential for tolerance development in chronic pain conditions remain unknown. Where This Paper Deserves Skepticism Animal pain models have limited translational validity to human chronic pain experience. The conditioned place preference paradigm, while established, represents an indirect measure of spontaneous pain that may not capture the complexity of human pain affect. Dr. Caplan's Take I find the dual mechanism compelling—addressing both sensory and affective pain components is exactly what we need in neuropathic pain management. However, I’ve seen too many promising preclinical pain studies fail in translation to get excited until we see human data with meaningful clinical endpoints. What a Careful Reader Should Take Away CB₂ receptor modulation represents a mechanistically rational approach to neuropathic pain that warrants clinical investigation. The preclinical evidence suggests potential advantages over current therapies, but human studies with robust endpoints are essential before drawing clinical conclusions. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Assessments%20of%20Evoked%20and%20Spontaneous%20Pain%20Following%20Administration%20of%20Gabapentin%20and%20the%20Cannabinoi...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcb2-receptor-agonist-neuropathic-pain-treatment-study%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcb2-receptor-agonist-neuropathic-pain-treatment-study%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Assessments%20of%20Evoked%20and%20Spontaneous%20Pain%20Following%20Administration%20of%20Gabapentin%20and%20the%20Cannabinoi...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcb2-receptor-agonist-neuropathic-pain-treatment-study%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) ## FAQ #### What is LY2828360 and how does it work for neuropathic pain? LY2828360 is a CB₂ cannabinoid receptor agonist that specifically targets [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) involved in pain modulation. This preclinical study demonstrates that chronic dosing (10 mg/kg) effectively reduces both evoked pain responses and spontaneous neuropathic pain in a spared nerve injury model. #### How does CB₂ receptor targeting differ from traditional cannabinoid approaches? CB₂ receptors are primarily located in immune cells and peripheral tissues, unlike CB₁ receptors that are concentrated in the brain and cause psychoactive effects. This selective targeting may allow for analgesic benefits without the cognitive or psychoactive side effects typically associated with cannabis-based medications. #### What types of neuropathic pain did this study evaluate? The researchers assessed both evoked pain (measurable responses to stimuli like pressure) and spontaneous pain (ongoing pain without external triggers). The study used paw withdrawal thresholds for evoked pain and conditioned place preference testing to evaluate the affective component of spontaneous pain. #### How significant were the pain reduction effects compared to existing treatments? LY2828360 demonstrated efficacy comparable to gabapentin, a standard neuropathic pain medication, in reducing both types of pain. The study showed that effective CB₂ agonism could prevent the preference behavior that injured rats typically show for environments associated with pain relief. #### What are the clinical implications for human neuropathic pain treatment? This research suggests that selective CB₂ receptor agonists could offer a novel therapeutic approach for neuropathic pain conditions without psychoactive effects. However, this is preclinical research in animal models, and human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) would be necessary to determine safety and efficacy in patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Pain Relief: Evidence-Based Clinical Guide](https://cedclinic.com/cannabinoid-pain-relief-evidence-based-clinical-guide/) A comprehensive guide on cannabinoid-based pain relief, highlighting clinical evidence and therapeutic considerations. [Read the Clinical Guide](https://cedclinic.com/cannabinoid-pain-relief-evidence-based-clinical-guide/) [Medical Cannabis for Autoimmune Pain Management According to Dr. Caplan](https://cedclinic.com/medical-cannabis-for-autoimmune-pain-relief-management/) Insights into medical cannabis use for autoimmune-related pain, including expert perspectives and patient considerations. [Explore Medical Cannabis Insights](https://cedclinic.com/medical-cannabis-for-autoimmune-pain-relief-management/) [Cannabis Essential Oil and Neuroinflammation in Multiple Sclerosis](https://cedclinic.com/cannabis-essential-oil-neuroinflammation-multiple-sclerosis-study/) Study on sesquiterpene-rich cannabis essential oil reducing neuroinflammation via CB2-mediated signaling in MS models. [Discover Neuroinflammation Research](https://cedclinic.com/cannabis-essential-oil-neuroinflammation-multiple-sclerosis-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).